VERAPAMIL HYDROCHLORIDE injection

Country: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

VERAPAMIL HYDROCHLORIDE (UNII: V3888OEY5R) (VERAPAMIL - UNII:CJ0O37KU29)

থেকে পাওয়া:

EXELA PHARMA SCIENCES, LLC

INN (International Name):

VERAPAMIL HYDROCHLORIDE

রচনা:

VERAPAMIL HYDROCHLORIDE 2.5 mg in 1 mL

প্রশাসন রুট:

INTRAVENOUS

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

থেরাপিউটিক ইঙ্গিত:

Verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: In controlled studies in the U.S., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous Verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after Verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. The effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. Because a small fraction (<1.0%) of patients treated with Verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation w

পণ্য সারাংশ:

All forms are individually packaged. Size NDC Number Carton Size 5-mg (2 ml) vial 51754-0203-2  5 5-mg (2 ml) vial 51754-0203-4  25 10-mg (4 mL) vial 51754-0205-2  5 Store at 59° to 86°F (15° to 30°C) [See USP Controlled Room Temperature.] The stopper in the Verapamil hydrochloride injection vial is formulated with a synthetic base-polymer and does not contain natural rubber latex.

অনুমোদন অবস্থা:

New Drug Application

পণ্য বৈশিষ্ট্য

VERAPAMIL HYDROCHLORIDE- VERAPAMIL HYDROCHLORIDE INJECTION
EXELA PHARMA SCIENCES, LLC
----------
VERAPAMIL
HYDROCHLORIDE INJECTION, USP
FOR INTRAVENOUS INJECTION
PROTECT FROM LIGHT
DESCRIPTION
Verapamil hydrochloride is a calcium antagonist or slow-channel
inhibitor available as a sterile
solution for intravenous injection in 5-mg (2 ml) and 10-mg (4 ml)
vials. Each form contains Verapamil
HCl 2.5 mg/ml and sodium chloride 8.5 mg/ml in water for injection.
Hydrochloric acid and/or sodium
hydroxide is used for pH adjustment. The pH of the solution is between
4.1 and 6.0.
The structural formula of verapamil HCl is given below:
Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]
methylamino]propyl]-3,4-dimethoxy-α-(1-
methylethyl) hydrochloride
Verapamil hydrochloride is an almost white, crystalline powder,
practically free of odor, with a bitter
taste. It is soluble in water, chloroform, and methanol. Verapamil
hydrochloride is not chemically
related to other antiarrhythmic drugs.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION: Verapamil inhibits the calcium ion (and possibly
sodium ion) influx through
slow channels into conductile and contractile myocardial cells and
vascular smooth muscle cells. The
antiarrhythmic effect of Verapamil appears to be due to its effect on
the slow channel in cells of the
cardiac conductile system.
Electrical activity through the SA and AV nodes depends, to a
significant degree, upon calcium influx
through the slow channel. By inhibiting this influx, Verapamil slows
AV conduction and prolongs the
effective refractory period within the AV node in a rate-related
manner. This effect results in a
reduction of the ventricular rate in patients with atrial flutter
and/or atrial fibrillation and a rapid
ventricular response. By interrupting reentry at the AV node,
Verapamil can restore normal sinus rhythm
in patients with paroxysmal supraventricular tachycardias (PSVT),
including Wolff-Parkinson-White
(WPW) syndrome. Verapamil has no effect on conduction across accessory
bypass tracts. Ver